ascendis news:致力推動創新療法,讓內分泌患者能盡情實現對生命的美好嚮往
致力推動創新療法,讓內分泌患者能盡情實現對生命的美好嚮往
NewsReleaseFDAAcceptsforPriorityReviewAscendisPharma'sNDAforTransCon™PTHinAdultPatientswithHypoparathyroidism.。其他文章還包含有:「AscendisPharmaAS(ASND)LatestPressReleases&...」、「AscendisPharmaAS(ASND)LatestStockNews&...」、「AscendisPharmaAS(ASND)StockPrice」、「AscendisPharmaReportsSecondQuarter2023Financial...」、「AscendisPharma」、「AscendisPharma」、「NewsReleases」
查看更多 離開網站Ascendis Pharma AS (ASND) Latest Press Releases & ...
https://finance.yahoo.com
Get the latest Ascendis Pharma A/S (ASND) stock news and headlines to help you in your trading and investing decisions.
Ascendis Pharma AS (ASND) Latest Stock News & ...
https://finance.yahoo.com
The FDA decision prevents Ascendis from labeling and marketing the new drug application for TransCon PTH. ASND stock plunged. Investor's Business Daily•5 months ...
Ascendis Pharma AS (ASND) Stock Price
https://finance.yahoo.com
Find the latest Ascendis Pharma A/S (ASND) stock quote, history, news and other vital information to help you with your stock trading and investing.
Ascendis Pharma Reports Second Quarter 2023 Financial ...
https://investors.ascendisphar
More information on the pre-clinical data can be found in a presentation here on the Investors & News section of the Ascendis Pharma website ...
Ascendis Pharma
http://investors.ascendispharm
News Releases. September 5, 2023. Ascendis Pharma Reports Second Quarter 2023 Financial Results. September 5, 2023. New Post Hoc Analysis Showed Substantial ...
Ascendis Pharma
https://ascendispharma.com
We apply our TransCon technology platform to build a leading, fully integrated biopharma company & make a meaningful difference for patients, ...
News Releases
https://investors.ascendisphar
News Releases · June 17, 2023. One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023 · June 13, 2023.